The impact of CYP3A5*3 polymorphism on sirolimus pharmacokinetics: insights from predictions with a physiologically‐based pharmacokinetic model

AIMS: Sirolimus is an mTOR inhibitor metabolized by CYP3A4 and CYP3A5. Reported effects of CYP3A5 polymorphisms on sirolimus pharmacokinetics (PK) have shown unexplained discrepancies across studies. We quantitatively assessed the effect of CYP3A5*3 status on sirolimus PK by in vitro assessment and...

Full description

Saved in:
Bibliographic Details
Published in:Br J Clin Pharmacol
Main Authors: Emoto, Chie, Fukuda, Tsuyoshi, Venkatasubramanian, Raja, Vinks, Alexander A.
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2015
Subjects:
Methods in Clinical Pharmacology
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4693485/
https://ncbi.nlm.nih.gov/pubmed/26256674
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12743
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items